Abstract: Low-grade serous ovarian carcinoma (LGSOC) is a rare, chemoresistant subtype of epithelial ovarian cancer frequently driven by alterations in the mitogen-activated protein kinase (MAPK) pathway. While targeted therapies such as MEK inhibitors have shown some clinical efficacy, their long-term utility is often hindered by adaptive resistance mechanisms. Defactinib (VS-6063) is a potent, orally bioavailable, second-generation inhibitor of focal adhesion kinase (FAK). By blocking FAK, defactinib overcomes the compensatory stromal and tumor-intrinsic resistance induced by RAF/MEK inhibition. In May 2025, the US Food and Drug Administration (FDA) granted accelerated approval to the co-packaged regimen of defactinib and the RAF/MEK clamp avutometinib for the treatment of adult patients with KRAS-mutated recurrent LGSOC. This review synthesizes the pharmacological activity, molecular mechanism of action, structure-activity relationship, current limitations, and future perspectives of defactinib in the management of LGSOC based on recent literature.
1. Introduction
Low-grade serous ovarian carcinoma (LGSOC) is a rare and molecularly distinct subtype of ovarian cancer, accounting for less than 5% of all epithelial ovarian carcinomas [3]. Clinically, LGSOC is characterized by a younger median age of onset, slow growth, high recurrence rates exceeding 80%, and a notoriously poor response to conventional platinum-based cytotoxic chemotherapy [3]. Unlike high-grade serous ovarian carcinoma, which is defined by genomic instability and ubiquitous TP53 mutations, LGSOC exhibits higher genomic stability and frequently harbors activating mutations in the MAPK signaling pathway, most notably in the KRAS, NRAS, and BRAF genes [3].
The reliance of LGSOC on the MAPK pathway has driven the clinical investigation of targeted therapies. However, single-node MEK inhibitors have demonstrated limited durability due to treatment-related toxicities and the rapid emergence of acquired resistance [1][3]. Defactinib (VS-6063) is a second-generation, orally administered small-molecule inhibitor targeting focal adhesion kinase (FAK) [1][2]. Recognizing the synergistic potential of dual-pathway blockade, the FDA granted accelerated approval on May 8, 2025, for the combination of defactinib and the RAF/MEK clamp avutometinib (Avmapki® Fakzynja® Co-pack) for the treatment of recurrent, KRAS-mutated LGSOC in patients who have received prior systemic therapy [1][3]. This marks a significant milestone as the first targeted therapy approved specifically for this rare ovarian cancer subtype [1].
2. Pharmacological Activity
The clinical efficacy of defactinib in LGSOC is most prominently demonstrated when utilized in combination with avutometinib. The pivotal data supporting its recent FDA approval derived from the Phase 2 RAMP-201 (ENGOT-ov60/GOG-3052) open-label trial, which evaluated the combination in 115 patients with recurrent LGSOC following prior chemotherapy [3]. In the molecularly selected cohort of patients with KRAS-mutated LGSOC (n=58), the combination achieved a confirmed objective response rate (ORR) of 44% and a median progression-free survival (PFS) of 22.0 months [3].
In contrast, patients with KRAS wild-type LGSOC (n=57) exhibited a lower ORR of 17% and a median PFS of 12.8 months, resulting in an overall ORR of 31% across the entire study population [3]. These findings confirm that defactinib significantly contributes to the observed antitumor activity and favorable disease control signal when paired with a MAPK pathway inhibitor [1]. To further validate these results, a Phase 3 randomized, open-label trial (GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301) is currently underway, comparing the efficacy of avutometinib plus defactinib against the investigator's choice of standard-of-care treatments in patients with recurrent LGSOC [2][3].
3. Molecular Mechanism of Action
FAK is a non-receptor cytoplasmic protein tyrosine kinase that plays a critical role in integrating signals from integrins and growth factor receptors. It regulates essential cellular processes including cell adhesion, migration, proliferation, survival, and the modulation of the tumor microenvironment [1][6]. Defactinib functions as an ATP-competitive inhibitor that potently blocks the autophosphorylation of FAK at the Tyrosine-397 (Y397) site in a time- and dose-dependent manner [2][4].
The mechanistic rationale for deploying defactinib in LGSOC centers on overcoming adaptive resistance. KRAS-mutant LGSOC relies heavily on chronic MAPK signaling for survival. While the RAF/MEK clamp avutometinib effectively suppresses this pathway, this inhibition inadvertently induces the compensatory activation of FAK and other parallel tumor growth pathways [3]. Defactinib specifically targets this adaptive resistance mechanism. By inhibiting FAK, defactinib not only impairs the invasive properties of the tumor cells but also disrupts FAK-mediated stromal and immune support that promotes tumor growth [1]. Consequently, the combination of avutometinib and defactinib simultaneously dismantles both tumor-intrinsic signaling and pro-tumor stromal resistance [1][3].
4. Structure-Activity Relationship (SAR)
Defactinib (also known as VS-6063 or PF-04554878) is a rationally designed, small-molecule ATP-competitive kinase inhibitor [1][5]. It targets the kinase catalytic domain of FAK and the closely related proline-rich tyrosine kinase 2 (Pyk2) [6]. Preclinical studies highlight its high potency, demonstrating an in vitro IC50 value for FAK ranging from 0.6 nM to 1.5 nM [2][5][6].
While defactinib also inhibits Pyk2 (with reported IC50 values between 0.6 nM and 2.4 nM), its selectivity for the FAK kinase domain is functionally significant and exceeds its affinity for Pyk2 [2][5][6]. By binding to the ATP active site, defactinib prevents the phosphorylation of the Y397 residue, which is the primary binding site for the SH2 domain of Src [2]. This structural blockade effectively disrupts downstream oncogenic signaling cascades, including the PI3K/AKT/mTOR pathways, thereby reducing cancer cell proliferation and inducing apoptosis [2][4].
5. Current Limitations
Despite its therapeutic promise, the clinical application of defactinib is accompanied by several limitations. First, the safety profile requires careful management. In the RAMP-201 trial, the combination of defactinib and avutometinib resulted in a 10% discontinuation rate due to adverse events (AEs) [3]. The most common grade ≥3 treatment-related AEs included elevated blood creatine phosphokinase (24%), diarrhea (8%), anemia (5%), and dermatitis acneiform (4%) [3]. Additionally, defactinib has been associated with Grade 1 or 2 unconjugated hyperbilirubinemia, resembling Gilbert's syndrome [2][6]. Overlapping toxicities with partner drugs, such as MAPK pathway-related rash or gastrointestinal toxicity, frequently necessitate dose interruptions or reductions [1].
Second, the efficacy of the defactinib/avutometinib combination is highly dependent on the patient's molecular profile, showing significantly lower response rates in KRAS wild-type LGSOC compared to KRAS-mutated disease [3]. Furthermore, identifying eligible patients non-invasively remains challenging; studies have shown that circulating tumor DNA (ctDNA) assays have a high false-negative rate (56%) for detecting KRAS mutations in LGSOC due to the low-shedding nature of these tumors [3]. Finally, the current FDA approval is based on single-arm, non-randomized cohort data, meaning the true comparative advantage over standard-of-care therapies remains provisional until Phase 3 data mature [1].
6. Future Perspectives
The immediate future of defactinib in LGSOC relies on the readout of the ongoing Phase 3 RAMP 301 trial, which will be critical for quantifying the incremental survival benefit of the defactinib/avutometinib combination against investigator's choice chemotherapy [1][3]. Given the accelerated approval pathway, post-marketing safety studies (PASS) will be essential to characterize any uncommon but serious toxicities associated with chronic administration in real-world patient populations [1].
Beyond LGSOC, defactinib is being actively investigated in other solid tumors where FAK overexpression or stromal resistance plays a key role. Ongoing trials are evaluating defactinib in combination with pembrolizumab and gemcitabine for refractory pancreatic ductal adenocarcinoma, and in combination with other targeted agents for KRAS-mutated non-small cell lung cancer (NSCLC) and NF2-mutated tumors [1][2][4]. Future research must also prioritize the development of more sensitive, LGSOC-specific liquid biopsy platforms to improve patient selection, as well as the exploration of novel combinations—such as integrating FAK inhibitors with CDK4/6 inhibitors or endocrine therapies—to further delay acquired resistance [3].
